Opendata, web and dolomites

ONCOTECT SIGNED

Early detection of tumor DNA in liquid biopsies as a biomarker of cancer recurrence

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ONCOTECT project word cloud

Explore the words cloud of the ONCOTECT project. It provides you a very rough idea of what is the project "ONCOTECT" about.

time    inexpensive    considerable    tumor    oncogenic    bv    market    radiological    genes    accurate    sme    lower    faster    diagnostics    vitro    full    underlying    breaking    critical    recurrent    ambition    ultra    relative    sensitive    patients    licensing    leveraging    cyclomics    types    unable    methodology    treatment    vision    examination    freedom    neck    dutch    opportunity    liquid    disrupt    ct    strategy    head    reliably    feasibility    hnc    blood    carry    circulating    fto    regulatory    mutations    spectrum    dna    care    delays    first    start    programs    commercialization    routine    encompassing    ground    diagnostic    survival    monitoring    operate    rates    competing    kit    company    cancer    sequencing    recurrence    samples    clinical    superior    quality    90    integration    proof    detecting    detect    cohort    initial    oncotect    lesions    proprietary    disease    gene    detection    ivd    remission    tp53    assay    death    decision    obtain    detects    biopsies    fast    screening    standard    workflow   

Project "ONCOTECT" data sheet

The following table provides information about the project.

Coordinator
CYCLOMICS BV 

Organization address
address: MOSKEEPLEIN 82
city: UTRECHT
postcode: 3531 BX
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website https://www.cyclomics.com/technology.html
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2019-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CYCLOMICS BV NL (UTRECHT) coordinator 50˙000.00

Map

 Project objective

Cyclomics BV is a Dutch start-up company with the ambition to disrupt the cancer diagnostics market with its proprietary circulating tumor (ct) DNA detection technology. Cyclomics has developed a ground-breaking sequencing methodology that enables reliable, fast and ultra-sensitive detection of cancer recurrence from blood samples (liquid biopsies). The first product, ONCOTECT, detects oncogenic mutations in the TP53 gene, and is developed for accurate and early detection of head and neck cancer (HNC) recurrence. Recurrent disease after initial remission is a main cause of cancer-related death. In HNC, radiological examination is the current standard in detecting cancer lesions but is unable to reliably detect recurrence early on, leading to treatment delays and lower survival rates. Integration of the ONCOTECT assay into routine clinical workflow is inexpensive and will provide faster time-to-results relative to competing sequencing methods. Since 90% of HNC patients carry specific oncogenic DNA mutations in the TP53 gene, the first application of this novel technology in recurrent HNC presents a considerable market opportunity for ONCOTECT. After achieving clinical proof-of-concept in a cohort of 20 patients, Cyclomics will offer its technology for licensing to a diagnostics company to further develop ONCOTECT as an in vitro diagnostic (IVD) kit and bring it to the market, with the aim of enabling superior quality in diagnostic and clinical decision making. ONCOTECT focuses on TP53 but the underlying technology can be applied to many different genes. Leveraging this potential, Cyclomics’ long-term vision includes monitoring of cancer treatment response and early screening programs, encompassing various genes and cancer types, with the potential to impact the full spectrum of cancer care. In this SME feasibility study, Cyclomics will obtain critical insight for commercialization strategy, including freedom to operate (FTO), user needs and regulatory requirements.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCOTECT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCOTECT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

CoLumbo (2019)

AUTOMATED DIAGNOSTICS AND RADIOLOGICAL READING FROM LUMBAR SPINE MRI

Read More  

ClosedToe (2020)

Sock toe closing system for circular knitting machines

Read More  

FIRESENSE (2019)

Flame Detector Based on Epitaxial Metal Oxides (EMO) Technology

Read More